Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Betere overleving na tripeltherapie bij BRAF V600E-gemuteerde colorectale kanker
jan 2020 | Maag-darm-leveroncologie